

#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

Jiang 1



| Section 1.                                                                                                                                                                                                                                                                                                            | Identifying Inform                                                                                | nation                                                      |                                        |                                                                                             |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|-------------------------------------------------------------|----------------------------------------|---------------------------------------------------------------------------------------------|
| 1. Given Name (Fi                                                                                                                                                                                                                                                                                                     | rst Name)                                                                                         | 2. Surname (Last Name)<br>Jiang                             |                                        | 3. Date<br>06-November-2019                                                                 |
| 4. Are you the cor                                                                                                                                                                                                                                                                                                    | responding author?                                                                                | ☐ Yes ✓ No                                                  | Corresponding Author's Nam<br>Jie Meng | ne                                                                                          |
| 5. Manuscript Title Clinical features                                                                                                                                                                                                                                                                                 |                                                                                                   | of 57 patients with prima                                   | ry tracheal tumors                     |                                                                                             |
| 6. Manuscript Ider                                                                                                                                                                                                                                                                                                    | ntifying Number (if you kr                                                                        | now it)                                                     |                                        |                                                                                             |
|                                                                                                                                                                                                                                                                                                                       |                                                                                                   |                                                             | _                                      |                                                                                             |
| Section 2.                                                                                                                                                                                                                                                                                                            | The Work Under Co                                                                                 | onsideration for Public                                     | cation                                 |                                                                                             |
| Did you or your institution <b>at any time</b> receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)? |                                                                                                   |                                                             |                                        |                                                                                             |
| Are there any relevant conflicts of interest?                                                                                                                                                                                                                                                                         |                                                                                                   |                                                             |                                        |                                                                                             |
| Section 3.                                                                                                                                                                                                                                                                                                            |                                                                                                   |                                                             |                                        |                                                                                             |
| Section 5.                                                                                                                                                                                                                                                                                                            | Relevant financial                                                                                | activities outside the s                                    | submitted work.                        |                                                                                             |
| of compensation clicking the "Add                                                                                                                                                                                                                                                                                     | ) with entities as descr<br>I +" box. You should re                                               | ibed in the instructions. Us<br>port relationships that wer |                                        | tionships (regardless of amount dd as many lines as you need by onths prior to publication. |
| Are there any rel                                                                                                                                                                                                                                                                                                     | evant conflicts of intere                                                                         | est? Yes ✓ No                                               |                                        |                                                                                             |
|                                                                                                                                                                                                                                                                                                                       |                                                                                                   |                                                             |                                        |                                                                                             |
| Section 4.                                                                                                                                                                                                                                                                                                            | Intellectual Proper                                                                               | rty Patents & Copyric                                       | yhts                                   |                                                                                             |
| Do you have any                                                                                                                                                                                                                                                                                                       | Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes Vo |                                                             |                                        |                                                                                             |

Jiang 2



| Section 5. Relationships not covered above                                                                                                                                                                                           |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Relationships not covered above                                                                                                                                                                                                      |
| Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?                                            |
| Yes, the following relationships/conditions/circumstances are present (explain below):                                                                                                                                               |
| ✓ No other relationships/conditions/circumstances that present a potential conflict of interest                                                                                                                                      |
| At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships. |
| Section 6. Disclosure Statement                                                                                                                                                                                                      |
| Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.                                                                                                    |
| Dr. Wang has nothing to disclose.Dr. Jiang has nothing to disclose.                                                                                                                                                                  |

#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Jiang 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your

Lei 1



| Section 1.                                                   | Identifying Inform                                 | nation                                                     |                                                                  |                                                                                                     |
|--------------------------------------------------------------|----------------------------------------------------|------------------------------------------------------------|------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------|
| 1. Given Name (Fir<br>Qunjuan                                | st Name)                                           | 2. Surname (Last Name)<br>Lei                              |                                                                  | 3. Date<br>06-November-2019                                                                         |
| 4. Are you the corr                                          | re you the corresponding author? Yes Vo            |                                                            | Corresponding Author's Nar<br>Jie Meng                           | me                                                                                                  |
| 5. Manuscript Title<br>Clinical features a                   |                                                    | of 57 patients with prima                                  | ry tracheal tumors                                               |                                                                                                     |
| 6. Manuscript Iden                                           | itifying Number (if you kr                         | now it)                                                    |                                                                  |                                                                                                     |
|                                                              |                                                    |                                                            | _                                                                |                                                                                                     |
| Section 2.                                                   | The Work Under Co                                  | onsideration for Publi                                     | cation                                                           |                                                                                                     |
| any aspect of the su<br>statistical analysis, o              | ubmitted work (including                           | but not limited to grants, da                              | a third party (government, cor<br>ata monitoring board, study de | mmercial, private foundation, etc.) for sign, manuscript preparation,                               |
| Section 3.                                                   |                                                    |                                                            |                                                                  |                                                                                                     |
| Place a check in to<br>of compensation;<br>clicking the "Add | he appropriate boxes i<br>) with entities as descr | ibed in the instructions. Us<br>port relationships that we | ether you have financial rela<br>se one line for each entity; a  | ationships (regardless of amount<br>dd as many lines as you need by<br>conths prior to publication. |
| Section 4.                                                   | Intellectual Proper                                | rty Patents & Copyri                                       | ghts                                                             |                                                                                                     |
| Do you have any                                              | patents, whether plan                              | ned, pending or issued, b                                  | roadly relevant to the work?                                     | Yes 🗸 No                                                                                            |

Lei 2



| Section 5. Polationships not severed above                                                                                                                                                                                           |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Relationships not covered above                                                                                                                                                                                                      |
| Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?                                            |
| Yes, the following relationships/conditions/circumstances are present (explain below):                                                                                                                                               |
| ✓ No other relationships/conditions/circumstances that present a potential conflict of interest                                                                                                                                      |
| At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships. |
| Section 6. Disclosure Statement                                                                                                                                                                                                      |
| Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.                                                                                                    |
| Dr. Wang has nothing to disclose.Dr. Lei has nothing to disclose.                                                                                                                                                                    |

#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Lei 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

Lv 1



| Section 1. Identifying Inform                                                                                                                                                                                                                                                                                         | nation                        |                                                                                                                                                                                  |  |  |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|--|
| 1. Given Name (First Name)<br>Xin                                                                                                                                                                                                                                                                                     | 2. Surname (Last Name)<br>Lv  | 3. Date<br>06-November-2019                                                                                                                                                      |  |  |
| 4. Are you the corresponding author? Yes ✓ No                                                                                                                                                                                                                                                                         |                               | Corresponding Author's Name<br>Jie Meng                                                                                                                                          |  |  |
| 5. Manuscript Title<br>Clinical features and prognosis analysis                                                                                                                                                                                                                                                       | s of 57 patients with prima   | ry tracheal tumors                                                                                                                                                               |  |  |
| 6. Manuscript ldentifying Number (if you k                                                                                                                                                                                                                                                                            | now it)                       |                                                                                                                                                                                  |  |  |
|                                                                                                                                                                                                                                                                                                                       |                               |                                                                                                                                                                                  |  |  |
| Section 2. The Work Under C                                                                                                                                                                                                                                                                                           | onsideration for Public       | cation                                                                                                                                                                           |  |  |
| Did you or your institution <b>at any time</b> receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)? |                               |                                                                                                                                                                                  |  |  |
| Are there any relevant conflicts of interest? Yes Vo                                                                                                                                                                                                                                                                  |                               |                                                                                                                                                                                  |  |  |
|                                                                                                                                                                                                                                                                                                                       |                               |                                                                                                                                                                                  |  |  |
| Section 3. Relevant financial                                                                                                                                                                                                                                                                                         | activities outside the        | submitted work.                                                                                                                                                                  |  |  |
| of compensation) with entities as descr                                                                                                                                                                                                                                                                               | ribed in the instructions. Us | ether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by re present during the 36 months prior to publication. |  |  |
| Are there any relevant conflicts of inter                                                                                                                                                                                                                                                                             | · ·                           |                                                                                                                                                                                  |  |  |
|                                                                                                                                                                                                                                                                                                                       |                               |                                                                                                                                                                                  |  |  |
| Section 4. Intellectual Prope                                                                                                                                                                                                                                                                                         | rty Patents & Copyric         | ghts                                                                                                                                                                             |  |  |
| Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes Vo                                                                                                                                                                                                                     |                               |                                                                                                                                                                                  |  |  |

Lv 2



| Section 5. Relationships not covered above                                                                                                                                                                                          |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?                                           |
| Yes, the following relationships/conditions/circumstances are present (explain below):  No other relationships/conditions/circumstances that present a potential conflict of interest                                               |
| At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statement On occasion, journals may ask authors to disclose further information about reported relationships. |
| Section 6. Disclosure Statement                                                                                                                                                                                                     |
| Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.                                                                                                   |
| Dr. Wang has nothing to disclose.Dr. Lv has nothing to disclose.                                                                                                                                                                    |

#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Lv 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your

Zou 1



| Section 1. Identifying Infor                                  | mation                                                         |                                                                                                                                                                                   |
|---------------------------------------------------------------|----------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1. Given Name (First Name)<br>Lijun                           | 2. Surname (Last Name)<br>Zou                                  | 3. Date<br>06-November-2019                                                                                                                                                       |
| 4. Are you the corresponding author?                          | Yes ✓ No                                                       | Corresponding Author's Name<br>Jie Meng                                                                                                                                           |
| 5. Manuscript Title<br>Clinical features and prognosis analys | is of 57 patients with prima                                   | ry tracheal tumors                                                                                                                                                                |
| 6. Manuscript Identifying Number (if you                      | know it)                                                       |                                                                                                                                                                                   |
|                                                               |                                                                | _                                                                                                                                                                                 |
| Section 2. The Work Under                                     | Consideration for Public                                       | cation                                                                                                                                                                            |
|                                                               | ng but not limited to grants, da                               | a third party (government, commercial, private foundation, etc.) for ata monitoring board, study design, manuscript preparation,                                                  |
| ,                                                             |                                                                |                                                                                                                                                                                   |
| Section 3. Relevant financia                                  | ıl activities outside the :                                    | submitted work.                                                                                                                                                                   |
| of compensation) with entities as desc                        | cribed in the instructions. Use<br>eport relationships that we | nether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by re present during the 36 months prior to publication. |
| ·                                                             |                                                                |                                                                                                                                                                                   |
| Section 4. Intellectual Prope                                 | erty Patents & Copyri                                          | ghts                                                                                                                                                                              |
| Do you have any patents, whether pla                          |                                                                |                                                                                                                                                                                   |

Zou 2



| Section 5. Polationships not sovered above                                                                                                                                                                                           |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Relationships not covered above                                                                                                                                                                                                      |
| Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?                                            |
| Yes, the following relationships/conditions/circumstances are present (explain below):                                                                                                                                               |
| ✓ No other relationships/conditions/circumstances that present a potential conflict of interest                                                                                                                                      |
| At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships. |
| Section 6. Disclosure Statement                                                                                                                                                                                                      |
| Disclosure Statement                                                                                                                                                                                                                 |
| Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.                                                                                                    |
| Dr. Wang has nothing to disclose.Dr. Zou has nothing to disclose.                                                                                                                                                                    |

#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Zou 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether

earning royalties or not

Royalties: Funds are coming in to you or your institution due to you

**Royalties:** Funds are coming in to you or your institution due to your patent

Liu 1



| Section 1. Id                                | entifying Informa                                                      | ition                                                                           |                                                                                                          |                                                                                                       |
|----------------------------------------------|------------------------------------------------------------------------|---------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------|
| 1. Given Name (First N<br>Jingjing           | ame)                                                                   | 2. Surname (Last Name<br>Liu                                                    | )                                                                                                        | 3. Date<br>06-November-2019                                                                           |
| 4. Are you the correspond                    | onding author?                                                         | ☐ Yes ✓ No                                                                      | Corresponding Author's Na<br>Jie Meng                                                                    | me                                                                                                    |
| 5. Manuscript Title<br>Clinical features and | prognosis analysis o                                                   | f 57 patients with prir                                                         | nary tracheal tumors                                                                                     |                                                                                                       |
| 6. Manuscript Identifyi                      | ing Number (if you kno                                                 | w it)                                                                           |                                                                                                          |                                                                                                       |
|                                              |                                                                        |                                                                                 |                                                                                                          |                                                                                                       |
| Section 2. Th                                | e Work Under Co                                                        | nsideration for Pul                                                             | olication                                                                                                |                                                                                                       |
|                                              | nitted work (including b<br>?                                          | out not limited to grants                                                       | data monitoring board, study de                                                                          | mmercial, private foundation, etc.) for esign, manuscript preparation,                                |
| Section 3. Re                                | levant financial a                                                     | ctivities outside th                                                            | e submitted work.                                                                                        |                                                                                                       |
| Place a check in the a                       | appropriate boxes in<br>th entities as describ<br>box. You should repo | the table to indicate we<br>ed in the instructions.<br>ort relationships that w | whether you have financial rel<br>Use one line for each entity; a<br>vere <b>present during the 36 n</b> | lationships (regardless of amount<br>add as many lines as you need by<br>nonths prior to publication. |
| Section 4. Int                               | tellectual Propert                                                     | y Patents & Copy                                                                | rights                                                                                                   |                                                                                                       |
| Do you have any pat                          | ents, whether planne                                                   | ed, pending or issued,                                                          | broadly relevant to the work?                                                                            | ? ☐ Yes ✓ No                                                                                          |

Liu 2



| Section 5. Relationships not covered above                                                                                                                                                                                            |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?                                             |
| Yes, the following relationships/conditions/circumstances are present (explain below):  No other relationships/conditions/circumstances that present a potential conflict of interest                                                 |
| At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships. |
| Section 6. Disclosure Statement                                                                                                                                                                                                       |
| Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.                                                                                                     |
| Dr. Wang has nothing to disclose.Dr. Liu has nothing to disclose.                                                                                                                                                                     |

#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Liu 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether

earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

Meng 1



| Section 1.                                      | Identifying Inform                                         | ation                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                  |
|-------------------------------------------------|------------------------------------------------------------|----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|
| 1. Given Name (First Name)<br>Jie               |                                                            | 2. Surname (Last Name)<br>Meng   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 3. Date<br>06-November-2019      |
| 4. Are you the corr                             | esponding author?                                          | ✓ Yes                            | No                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                  |
| 5. Manuscript Title<br>Clinical features a      |                                                            | of 57 patients                   | s with primary tracheal tumors                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                  |
| 6. Manuscript Iden                              | ntifying Number (if you kno                                | ow it)                           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                  |
|                                                 |                                                            |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                  |
| Section 2.                                      | The Work Under Co                                          | u ai dayati a                    | n fay Dublication                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                  |
| any aspect of the su<br>statistical analysis, e | titution <b>at any time</b> receivubmitted work (including | ve payment or<br>but not limited | services from a third party (government, condition of the grants, data monitoring board, study d                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                  |
| Section 3.                                      | Relevant financial a                                       | activities ou                    | utside the submitted work.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                  |
| of compensation)<br>clicking the "Add           | ) with entities as descril                                 | bed in the ins<br>ort relationsh | indicate whether you have financial restructions. Use one line for each entity; hips that were <b>present during the 36</b> where were present during the 36 where were presented by the second during the 36 where we were presented by the 36 where we will be a second during the 36 where we will be a second during the 36 where we will be a second during the 36 where we will be a second during the 36 where we will be a second during the 36 where we will be a second during the 36 where we will be a second during the 36 where we will be a second during the 36 where we will be a second during the 36 where we will be a second during the 36 where we will be a second during the 36 where we will be a second during the 36 where we will be a second during the 36 where we will be a second during the 36 where we will be a second during the 36 where we will be a second during the 36 where we will be a second during the 36 where we will be a second during the 30 where we will be a second during the 30 where we will be a second during the 30 where we will be a second during the 30 where we will be a second during the 30 where we will be a second during the 30 where we will be a second during the 30 where we will be a second during the 30 where we will be a second during the 30 where we will be a second during the 30 where we will be a second during the 30 where we will be a second during the 30 where we will be a second during the 30 where we will be a second during the 30 where we will be a second during the 30 where we will be a second during the 30 where we will be a second during the 30 where we will be a second during the 30 where we will be a second during the 30 where we will be a second during the 30 where we will be a second during the 30 where we will be a second during the 30 where we will be a second during the 30 where we will | add as many lines as you need by |
| Section 4.                                      | Intellectual Proper                                        | ty Datont                        | s & Convrights                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                  |
|                                                 |                                                            |                                  | or issued, broadly relevant to the work                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | k? ☐ Yes ✓ No                    |

Meng 2



| Section 5. Polationships not severed above                                                                                                                                                                                           |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Relationships not covered above                                                                                                                                                                                                      |
| Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?                                            |
| Yes, the following relationships/conditions/circumstances are present (explain below):                                                                                                                                               |
| ✓ No other relationships/conditions/circumstances that present a potential conflict of interest                                                                                                                                      |
| At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships. |
| Section 6. Disclosure Statement                                                                                                                                                                                                      |
| Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.                                                                                                    |
| Dr. Wang has nothing to disclose.Dr. Meng has nothing to disclose.                                                                                                                                                                   |

#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Meng 3